Cancer Incidence in People With Glomerular Disease: A Population-Level Study bit.ly/4smBPMv (OPEN ACCESS)

Hemodiafiltration: A Mini Review bit.ly/4awrvuf

✨ CSN and CKD-N are happy to welcome Dorry Segev from the USA as keynote speaker for this morning’s joint session on Artificial Intelligence 👨🏻‍🏫 #csnagm #csnscn #ai

The big experiment failed Giving bonuses and penalizing for performance to increase home dialysis and transplant did nothing. An RCT jamanetwork.com/journals/jam... in JAMA health forum

The man, the myth, the legend!

The healthcare costs of the forest fires Making the point we *cannot* afford not to plan #CSNAGM

Wanna reduce burnout? Less mandatory courses and more AI! #csnagm #csnscn

Don’t let previous abnormal surgeries to be a barrier for PD catheter insertion. But, the presence of adhesions has been associated with worse outcomes #csnagm #csnscn

Player to has entered: CRB2 the second podocyte autoantigen. #csnagm #csnscn

📢✨Join us today for the opening session of the 2026 CSN-AGM! Welcome to all attendees in Quebec City & to those following us online from afar! 👋 #csnagm #csnscn

#RenalPath: Diffuse granular capillary wall staining for phospholipase A2 receptor (PLA2R). PLA2R staining is positive in approximately 70% of patients with clinically idiopathic membranous nephropathy (immunofluorescence microscopy, PLA2R). bit.ly/2xVkJzs (FREE)

Heard that Twitter is imploding. Good riddance

@hswapnil.medsky.social @kidneyboy.bsky.social What’s the name of the nephrology song you play at the end of the podcast?

The second sibeprenlimab paper in @nejm.org (At least we gave it an oral at #KidneyWk unlike the poster for the phase 2 data in 2023!) www.nejm.org/doi/full/10....

And it’s live Iptacopan in C3GN makes it to @thelancet.com www.thelancet.com/journals/lan... #NephSky

Amazing to me that a seemingly acute event is either A) has long-term sequellae despite being apparently resolving or B) a dramatic and early presentation of profound endothelial disease

Way scarier story. Stories. www.nytimes.com/2025/06/13/t... (Gift link)

Sibeprenlimab in IgA Nephropathy #ERA25 * Data presented is the 9-month reduction in proteinuria

Dr Meghan Sise presenting on serum cr/cystatin outcomes in patients treated with cisplatin or carboplatin #Onconeph #ERA25

Hyperkalemia rates not lower with adding a flozin to the MRA 🤔 www.nejm.org/doi/full/10.... #ERA25

The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....

In the CONFIDENCE trial in persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results: nej.md/4jEVbbk #ERA25 #MedSky #Nephrology

@kevinyau.bsky.social GLP1 agonist master Jedi presenting at #ERA25. 💉GLP1 agonist reduce ED visits and hospitalizations!!! 📉Awesome methods. Best of the session: 💊DDP4 for comparison, IPTW, ICES data. Ticking all the right boxes (EPI nerd). 💊Only 40% on SGLT2i!!! We should flozinate more!!!

#ERA25 baby!!!

Experiential Evidence of Systemic Racism for Indigenous Peoples Navigating Transplantation in Canada - in @kireports.bsky.social www.kireports.org/article/S246... #NephSky

The US spends billions of dollars on binders every year We are doing the RCT to get you the answer - more than 3000 enrolled ajkdblog.org/2021/06/16/c... and www.nephjc.com/news/2021/2/...

Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. This study found no meaningful pharmacokinetic/pharmacodynamic advantages for torsemide versus furosemide. bit.ly/JASN0481

Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production #Nephrology #endocrinology #Diabetes #SGLT2i #NephSky www.tandfonline.com/doi/full/10....

Case report: Daratumumab for Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits in Kidney Allograft: A Case Report https://buff.ly/3P5dsSc

Feliz Navidad!

💡 Kidney stone patients not meeting their fluid intake goals? Try this one weird trick! Sprinkle a little Carolina reaper powder on their food a couple times a day and 💦🆙 they'll be drinking so much water you'll be looking up the latest #NephJC on hyponatremia correction rates! GI docs hate him!

Cumulative Blood Pressure Load and Incident CKD https://bit.ly/4eEtmx7 #OpenAccess #VisualAbstract

Nope we use the patients usual dwell volume

Is there any preferred dwell volume for IP antibiotics? @pd-perls.bsky.social #askrenal #nephsky

Prevent kidney failure to reduce carbon emissions ♻️ 🍃 🏭 Our new analysis of CREDENCE assessing environmental impacts from ⬇️ hospitalisations & dialysis 🏥 with SGLT2i SGLT2i ⬇️ greenhouse gas emissions from inpatient bed days & dialysis by 20% (39 kg CO2e per yr) www.thelancet.com/journals/lan...

Kidney biopsy on aspirin, nay or yay? I am interested in your type 1, blink of an eye, kind of reasoning. Is Dr Glassock yet in Blue Sky? #askrenal #nephsky @kidneyboy.bsky.social

Deleting X account today. #bluesky all the way

23 million

Reposting (fixed link): Check out our new and improved KFRE calculator with a nice visualization of kidney risk plotted on a KDIGO heatmap. For easy reference, go to ukidney.com/kfre ✨ New features: • Interactive KDIGO heatmap • Clear risk visualization

Ever need help converting between different steroid doses or different immunosuppressive agents in transplant? • Envarsus to Cyclosporine IV? • Astagraf/Advagraf to Envarsus? • Prednisone to Solucortef? • And many more? We have you covered! ukid.io/drugs

Others have noted it but I will too: The big reason Bluesky is so hot right now is that the people who add value to social media - the frequent posters in specific fields - are here now, talking to each other and creating the "spectator value" that draws users and attention.

🦋will hit 22 million users tonight 🐦 & 🧵 have many magnitudes more users But it’s the quality and not the quantity of users that gives BlueSky the edge, says @jaypeters.net at @theverge.com www.theverge.com/2024/11/23/2... h/t @kidneyboy.bsky.social via @scalzi.com

Just finished a smooth migration of prior X tweets to @bsky.app. Shout-out to @marcomaroni.it for the excellent code! 🔥https://github.com/marcomaroni-github/twitter-to-bluesky #NephSky #MedSky #NewHorizons

How do we feel about this study (DAPA advKD)? www.medscape.com/viewarticle/... Does it answer the Q of initiating SGLT2-I in adv CKD? Are the numbers enough? #nephsky @kidneyboy.bsky.social @hswapnil.bsky.social @freelyfiltered.bsky.social Maybe another one that could be discussed..

I hope that people who took an Ancestry or a 23&Me or simply had a relative who was sequenced for their cancer treatment understand they are one hack away from them and their facilities before they become uninsurable or unemployable once #GINA is revoked along with the ACA.

Hot take for #nephsky. I dislike the common use AKI for anyone with an elevated creatinine. Neither volume contraction nor obstruction cause significant injury. I find this use decreases thinking.

‘A place of joy’: why scientists are joining the rush to Bluesky @natureportfolio.bsky.social #NephSky #MedSky www.nature.com/articles/d41...